COLO.B.DK

731.2

0%↓

GMAB.DK

1,366

-2.67%↓

ZEAL.DK

552

+3.18%↑

HLUNB.DK

36.74

+0.93%↑

AMBUB.DK

123.8

+3%↑

COLO.B.DK

731.2

0%↓

GMAB.DK

1,366

-2.67%↓

ZEAL.DK

552

+3.18%↑

HLUNB.DK

36.74

+0.93%↑

AMBUB.DK

123.8

+3%↑

COLO.B.DK

731.2

0%↓

GMAB.DK

1,366

-2.67%↓

ZEAL.DK

552

+3.18%↑

HLUNB.DK

36.74

+0.93%↑

AMBUB.DK

123.8

+3%↑

COLO.B.DK

731.2

0%↓

GMAB.DK

1,366

-2.67%↓

ZEAL.DK

552

+3.18%↑

HLUNB.DK

36.74

+0.93%↑

AMBUB.DK

123.8

+3%↑

COLO.B.DK

731.2

0%↓

GMAB.DK

1,366

-2.67%↓

ZEAL.DK

552

+3.18%↑

HLUNB.DK

36.74

+0.93%↑

AMBUB.DK

123.8

+3%↑

Search

Novo Nordisk A-S (Class B)

Closed

473.9 -1.61

Overview

Share price change

24h

Current

Min

473.7

Max

475.85

Key metrics

By Trading Economics

Income

929M

28B

Sales

14B

86B

P/E

Sector Avg

23.043

73.239

EPS

6.34

Dividend yield

3.03

Profit margin

32.947

Employees

76,302

EBITDA

4.1B

39B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+9.53% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.03%

3.06%

Next Earnings

7 May 2025

Market Stats

By TradingEconomics

Market Cap

231B

2.3T

Previous open

475.51

Previous close

473.9

Novo Nordisk A-S (Class B) Chart

Past performance is not a reliable indicator of future results.

Related News

25 Feb 2025, 15:33 UTC

Major Market Movers

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

5 Feb 2025, 11:53 UTC

Earnings

Novo Nordisk Outlook Provides Some Welcome Relief -- 2nd Update

5 Feb 2025, 08:19 UTC

Earnings

Novo Nordisk Expects Slowing Sales Growth This Year -- Update

28 Mar 2025, 15:11 UTC

Market Talk

Novo Nordisk First Quarter Earnings Could Disappoint, BofA Says -- Market Talk

27 Mar 2025, 13:45 UTC

Market Talk
Earnings

Novo Nordisk's Wegovy Sales Growth Stalls in U.S. Amid Competition, Reimbursement Hurdles -- Market Talk

24 Mar 2025, 10:19 UTC

Market Talk

Novo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk

24 Mar 2025, 09:08 UTC

Market Talk
Earnings

Novo Nordisk Shares Could Remain Under Pressure for Now -- Market Talk

19 Mar 2025, 15:54 UTC

Top News

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

11 Mar 2025, 15:31 UTC

Market Talk

Novo Nordisk's CagriSema Trial Shows Disappointing Weight Loss -- Market Talk

11 Mar 2025, 14:58 UTC

Market Talk

Novo Nordisk's CagriSema Results Fail to Impress -- Market Talk

28 Feb 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

10 Feb 2025, 12:00 UTC

Top News

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7 Feb 2025, 10:30 UTC

Top News

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 Feb 2025, 16:16 UTC

Top News
Earnings

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6 Feb 2025, 14:56 UTC

Earnings

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

5 Feb 2025, 13:59 UTC

Earnings

Novo Nordisk Outlook Provides Some Welcome Relief -- WSJ

5 Feb 2025, 12:02 UTC

Earnings

Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns. -- Barrons.com

5 Feb 2025, 11:35 UTC

Market Talk
Earnings

Novo Nordisk's Earnings Report Should Get It Back On Track -- Market Talk

5 Feb 2025, 10:10 UTC

Hot Stocks

Stocks to Watch Wednesday: AMD, Alphabet, Novo Nordisk -- WSJ

5 Feb 2025, 09:43 UTC

Earnings

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

5 Feb 2025, 08:47 UTC

Market Talk
Earnings

Novo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk

5 Feb 2025, 08:38 UTC

Market Talk
Earnings

Novo Nordisk Earnings, Guidance Imply Consensus Upgrades -- Market Talk

5 Feb 2025, 08:32 UTC

Earnings

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

5 Feb 2025, 08:30 UTC

Market Talk
Earnings

Novo Nordisk Sales Guidance Materially Ahead of Expectations -- Market Talk

5 Feb 2025, 06:46 UTC

Earnings

Novo Nordisk Expects to File For First Regulatory Approval of CagriSema During 1Q26

5 Feb 2025, 06:45 UTC

Earnings

Novo Nordisk Plans to Initiate New CagriSema Phase 3 Trial in 2025 to Further Explore Weight Loss Potential

5 Feb 2025, 06:43 UTC

Earnings

Novo Nordisk: 2025 Free Cash Flow Expected to be DKK75B-DKK85B

5 Feb 2025, 06:42 UTC

Earnings

Novo Nordisk: 2025 Capex Expected to be Around DKK65B, Reflecting Expansion of Global Supply Chain

5 Feb 2025, 06:39 UTC

Earnings

Novo Nordisk: Sales Growth Has Resulted in Periodic Supply Constraints and Related Drug Shortage Notifications

5 Feb 2025, 06:39 UTC

Earnings

Novo Nordisk: Sales Growth Positively Impacted by Gross-to-Net Adjustments in U.S.

Peer Comparison

Price change

Novo Nordisk A-S (Class B) Forecast

Price Target

By TipRanks

9.53% upside

12 Months Forecast

Average 1,162.73 DKK  9.53%

High 1,550 DKK

Low 720 DKK

Based on 11 Wall Street analysts offering 12 month price targets forNovo Nordisk A-S (Class B) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

7

Buy

2

Hold

2

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.